Creative Biolabs offers a wide selection range of Chimeric Antigen Receptor (CAR) construct products targeting many different tumor associated antigens respectively. Meanwhile, our elite CAR construction products, such as lentivirus and retrovirus particles, have the best performance in both research and industry field. As the first-in-class biotech developer and provider, scientists of Creative Biolabs focus on applying outstanding technologies to the discovery and development of potential therapeutic approaches, such as custom CARs construction services. Besides the service of CAR construction, expression and purification, we also provide Quality Controls Measures which guarantee the CAR construction products with the highest quality and outstanding performance.
Chimeric antigen receptors (CARs) are composed of an extracellular antigen binding domain [usually a single-chain variable fragment (scFv) derived from monoclonal antibody] linked to the transmembrane domain which is followed by cytoplasmic signaling domains. Upon binding to the scFv specific antigen, the genetically modified CAR-T cells carry out the effector functions, and subsequently trigger the cytotoxicity depended lysis of tumor cells. The effectiveness of the CAR immunotherapy has been proved in a variety of animal models, nowadays, many clinical trials (from first to third generation CARs) with CAR-based genetically engineered T lymphocytes for treating diverse cancers are ongoing. Creative Biolabs has established a unique unparalleled CAR construction and production platform, which has achieved significant contribution to the development of this powerful technology.
Associated malignancy | Target antigen | Receptor type | CARs generation |
Leukemia | CD19 | ScFv-CD28-41BB-CD3ζ | Third |
CD19 | ScFv-CD28 | Second | |
CD19 | ScFv-41BB-CD3ζ | Second | |
k-light chain | ScFv-CD3ζ (VZV) | First | |
CD33 | ScFv-CD28-CD3ζ | Second | |
CD33 | ScFv-41BB-CD3ζ | Second | |
CD123 | ScFv-CD28-CD3ζ | Second | |
WT1 | ScFv-41BB-CD3ζ | Second | |
Pr3 | ScFv-41BB-CD3ζ | Second | |
Lymphoma | CD20 | ScFv-CD28-CD3ζ | Second |
CD19 | ScFv-CD28-41BB-CD3ζ | Third | |
CD22 | ScFv-CD28-CD3ζ | Second | |
k-light chain | ScFv-CD3ζ (VZV) | First | |
CD19 | ScFv-b2c-CD3ζ | Second | |
CD19 | ScFv -CD3ζ | First | |
CD19 | ScFv-41BB-CD3ζ | Second | |
CD30 | ScFv-CD28-CD3ζ | Second | |
Breast and others | erb-B2 | ScFv-CD28mut-CD3ζ | Second |
erb-B2 | ScFv-CD28-OX40-CD3ζ | Third | |
erb-B 2,3,4 | ScFv-CD3ζ | First | |
MUC1 | ScFv-FcεRIγ | First | |
LeY | ScFv-CD3ξ | First | |
Prostate cancer | erb-B2 | ScFv-CD3ζ | First |
PSCA | scFv-FcεRIγ | First | |
Colorectal cancer | EGP-40 | ScFv-CD28-CD3ζ vs. CD3ζ | Second |
erb-B2 | ScFV-CD28-FcεRIγ | Second | |
Lung malignancy | Her2/neu | ScFv-CD3ζ | First |
Adenocarcinomas | TAG-72 | ScFv-FcεRIγ (alloantigen) | First |
Cervical carcinoma | CD44v7/8 | ScFv-CD28-CD3ζ | Second |
Melanoma | GD3 | ScFv-CD3ζ | First |
MAGE-A1 | ScFv-CD4-CD3ζ | Second | |
Renal cell carcinoma | CAIX | ScFv-CD3ζ(EBV) | First |
Epithelial derived tumors | LeY | ScFv-CD3ξ | First |
Advanced osteosarcoma< | Her2/neu | scFv-CD3ζ | First |
Rhabdomyosarcoma | Fetal acethylcholine receptor | ScFv-CD3ζ | First |
Ewing’s | GD2 | ScFv-CD3ζ | First |
sarcoma | NKG2D | ScFv-CD28-CD3ζ | Second |
MUC1 | ScFv-4-1BB-CD3ζ | Second | |
survivin | ScFv-CD28-4-1BB-CD3ζ | Third | |
CSPG4 | ScFv-CD28-4-1BB-CD3ζ | Third | |
Medulloblastoma | Her2/neu | ScFv-CD3ζ | First |
IL-13R-a2 | ScFv-CD3ζ (Influenza MP-1) | First | |
Neuroblastoma | GD2 | ScFv-CD3ζ | First |
GD2 | ScFv-iC9-GD2-CD28-OX40 | Third | |
L1 cell adhesion molecule | ScFv-CD3ξ | First | |
CD171 | ScFv-CD28-4-1BB-CD3ζ | Third | |
EGFRvIII | ScFv-CD28-4-1BB-CD3ζ | Third | |
ROR1 | ScFv-CD28-4-1BB-CD3ζ | Third | |
Ovarian cancer | α-Folate receptor | ScFv-CD28/4-1BB-CD3ζ | Second |
FBP | ScFv-CD3ζ | First | |
MUC1 | ScFv-FcεRIγ | First | |
Glioma | Her2/neu | scFv-CD3ζ | First |
IL-13R-a2 | ScFv-CD3ζ (EBV) | First | |
Multiple malignancies | EGP-2 | ScFv-CD28-CD3ζ (Influenza) | Second |
EGP-2 | ScFv-CD28-CD3ζ | Second | |
Various tumors | Mesothelin | ScFV-CD4-FcεRIγ | Second |
Mesothelin | ScFv-CD8-CD3ζ | Second | |
Mesothelin | ScFv-FceRIγ | First | |
NKG2D ligands | ScFv-FcεRIγ | First | |
Tumor neovasculature | KDR | ScFV-CD3ζ (vaccination) | First |
VEGF-R2 | ScFv-FcεRIγCAIX | First | |
Prostate/tumor vasculature | PSMA | ScFv-FcεRIγ | First |
Virus (CMV or EBV or adenovirus) | CD28 | ScFv-FcεRIγ | First |
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.